Welcome to Equity.Guru’s Roundtable where our writers weigh in on the pros and cons of a spotlight company, break out where they see value, and help you avoid public markets pitfalls.
Today, we return Filament Health (FH.NEO), a Canadian-based psychedelics company focused on the natural extraction and delivery of psilocybin compounds for mental health therapies. With IP, revenue-generating deals and advancing clinical trials, Filament has more on the ball than most in the sector and is priced at a bargain.
Enjoy!
Filament Health (FH.NEO) – Investor Roundtable Video #7